The Journal of Practical Medicine >
New targets for the treatment of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Received date: 2024-10-25
Online published: 2025-03-20
Allogeneic haematopoietic stem cell transplantation （allo-HSCT） is the most effective curative treatment for hematologic malignancies. Its efficacy hinges on eliminating primary hematological disorders and restoring bone marrow hematopoiesis during conditioning， as well as leveraging the graft-versus-leukemia （GVL） effect. However， acute graft-versus-host disease （aGVHD） remains a significant complication following allo-HSCT， substantially affecting patient survival and quality of life. Current preclinical studies focus on strategies to mitigate aGVHD while preserving adequate GVL effects to improve transplant outcomes. This review summarizes recent preclinical research findings in this field， emphasizing the regulatory roles and specific molecular mechanisms of T cells， antigen-presenting cells， myeloid-derived suppressor cells， and mesenchymal stem cells in aGVHD. It further highlights the latest therapeutic strategies for aGVHD from preclinical studies， aiming to provide valuable insights for researchers and clinicians to develop more effective therapeutic targets and strategies.
Haoliang DUAN , Yuhua RU , Jia. CHEN . New targets for the treatment of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J]. The Journal of Practical Medicine, 2025 , 41(5) : 634 -640 . DOI: 10.3969/j.issn.1006-5725.2025.05.003
| 1 | HILL G R， KOYAMA M. Cytokines and costimulation in acute graft-versus-host disease ［J］. Blood， 2020， 136（4）： 418-428. doi:10.1182/blood.2019000952 |
| 2 | JAMY O， ZEISER R， CHEN Y B. Novel developments in the prophylaxis and treatment of acute GVHD ［J］. Blood， 2023， 142（12）： 1037-1046. doi:10.1182/blood.2023020073 |
| 3 | 张玉培， 谢新生， 石雅洁， 等. 异基因造血干细胞移植治疗ASXL1基因突变的骨髓增生异常综合征患者的效果 ［J］. 实用医学杂志， 2023， 39（23）： 3087-3092. doi:10.3969/j.issn.1006-5725.2023.23.011 |
| 4 | PACZESNY S. Discovery and validation of graft-versus-host disease biomarkers ［J］. Blood， 2013， 121（4）： 585-594. doi:10.1182/blood-2012-08-355990 |
| 5 | JIANG H， FU D， BIDGOLI A， et al. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor ［J］. Front Immunol， 2021， 12： 761448. doi:10.3389/fimmu.2021.761448 |
| 6 | ZHAO K， RUAN S， YIN L， et al. Dynamic regulation of effector IFN-γ-producing and IL-17-producing T cell subsets in the development of acute graft-versus-host disease ［J］. Mol Med Rep， 2016， 13（2）： 1395-1403. doi:10.3892/mmr.2015.4638 |
| 7 | KARL F， HUDECEK M， BERBERICH-SIEBELT F， et al. T-Cell Metabolism in Graft Versus Host Disease ［J］. Front Immunol， 2021， 12： 760008. doi:10.3389/fimmu.2021.760008 |
| 8 | CAMPE J， ULLRICH E. T Helper Cell Lineage-Defining Transcription Factors： Potent Targets for Specific GVHD Therapy？ ［J］. Front Immunol， 2021， 12： 806529. doi:10.3389/fimmu.2021.806529 |
| 9 | CHOE H， FERRARA J L M. New therapeutic targets and biomarkers for acute graft-versus-host disease （GVHD） ［J］. Expert Opin Ther Targets， 2021， 25（9）： 761-771. doi:10.1080/14728222.2021.1992383 |
| 10 | FISCHER J C， BSCHEIDER M， G?TTERT S， et al. Type I interferon signaling before hematopoietic stem cell transplantation lowers donor T cell activation via reduced allogenicity of recipient cells ［J］. Sci Rep， 2019， 9（1）： 14955. doi:10.1038/s41598-019-51431-2 |
| 11 | THANGAVELU G， DU J， PAZ K G， et al. Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease ［J］. Blood， 2020， 135（1）： 28-40. doi:10.1182/blood.2019000032 |
| 12 | MIAO S， TANG B， LIU H， et al. CXCR3 blockade combined with cyclosporine A alleviates acute graft-versus-host disease by inhibiting alloreactive donor T cell responses in a murine model ［J］. Mol Immunol， 2018， 94： 82-90. doi:10.1016/j.molimm.2017.12.010 |
| 13 | HUANG Y， ZOU Y， JIAO Y， et al. Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect ［J］. Front Immunol， 2022， 13： 751296. doi:10.3389/fimmu.2022.751296 |
| 14 | LIU Y， WU Y， WANG Y， et al. IL-35 mitigates murine acute graft-versus-host disease with retention of graft-versus-leukemia effects ［J］. Leukemia， 2015， 29（4）： 939-946. doi:10.1038/leu.2014.310 |
| 15 | SCHUTT S D， WU Y， KHAREL A， et al. The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease ［J］.J Clin Invest，2022，132（21）：e143950. doi:10.1172/jci143950 |
| 16 | GAO Y， SHAN W， GU T， et al. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration ［J］. Front Immunol， 2021， 12： 785774. doi:10.3389/fimmu.2021.785774 |
| 17 | WANG Q， SU X， HE Y， et al. CD11c participates in triggering acute graft-versus-host disease during bone marrow transplantation ［J］. Immunology， 2021， 164（1）： 148-160. doi:10.1111/imm.13350 |
| 18 | ZHU F， QIU T， ZHU S， et al. TIRC7 inhibits Th1 cells by upregulating the expression of CTLA?4 and STAT3 in mice with acute graft?versus?host disease ［J］. Oncol Rep， 2020， 44（1）： 43-54. |
| 19 | YAO Y， WANG L， ZHOU J， et al. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect ［J］. J Transl Med， 2017， 15（1）： 28. doi:10.1186/s12967-017-1132-9 |
| 20 | WU Y， BASTIAN D， SCHUTT S， et al. Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice ［J］. Biol Blood Marrow Transplant， 2015， 21（7）： 1195-1204. doi:10.1016/j.bbmt.2015.03.016 |
| 21 | IM K I， KIM N， LIM J Y， et al. The Free Radical Scavenger NecroX-7 Attenuates Acute Graft-versus-Host Disease via Reciprocal Regulation of Th1/Regulatory T Cells and Inhibition of HMGB1 Release ［J］. J Immunol， 2015， 194（11）： 5223-5232. doi:10.4049/jimmunol.1402609 |
| 22 | HE Y S， YANG X K， HU Y Q， et al. Emerging role of Fli1 in autoimmune diseases ［J］. Int Immunopharmacol， 2021， 90： 107127. doi:10.1016/j.intimp.2020.107127 |
| 23 | GONG H， MA S， CHEN J， et al. Dendritic cell-derived IL-27 p28 regulates T cell program in pathogenicity and alleviates acute graft-versus-host disease ［J］. Signal Transduct Target Ther， 2022， 7（1）： 319. doi:10.1038/s41392-022-01147-z |
| 24 | LIU H， YU Z， TANG B， et al. LYG1 Deficiency Attenuates the Severity of Acute Graft-Versus-Host Disease via Skewing Allogeneic T Cells Polarization Towards Treg Cells ［J］. Front Immunol， 2021， 12： 647894. doi:10.3389/fimmu.2021.762728 |
| 25 | WU Y， TANG C-H A， MEALER C， et al. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function ［J］. Cell Mol Immunol， 2021， 18（3）： 632-643. doi:10.1038/s41423-020-00611-6 |
| 26 | GAO Z， GAO Z， ZHANG H， et al. Targeting STING： From antiviral immunity to treat osteoporosis ［J］. Front Immunol， 2022， 13： 1095577. doi:10.3389/fimmu.2022.1095577 |
| 27 | MENDIRATTA M， MENDIRATTA M， GANGULY S， et al. Concurrent hypoxia and apoptosis imparts immune programming potential in mesenchymal stem cells： Lesson from acute graft-versus-host-disease model ［J］. Stem Cell Res Ther， 2024， 15（1）： 381. doi:10.1186/s13287-024-03947-2 |
| 28 | MURRAY P J， ALLEN J E， BISWAS S K， et al. Macrophage activation and polarization： Nomenclature and experimental guidelines ［J］. Immunity， 2014， 41（1）： 14-20. doi:10.1016/j.immuni.2014.06.008 |
| 29 | LIU X， SU Y， SUN X， et al. Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization ［J］. Sci China Life Sci， 2020， 63（11）： 1744-1754. doi:10.1007/s11427-019-1691-x |
| 30 | SU Y， SUN X， LIU X， et al. hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype ［J］. J Hematol Oncol， 2022， 15（1）： 99. doi:10.1186/s13045-022-01323-2 |
| 31 | KUBOTA N， SAITO A， TANAKA R， et al. Langerhans Cells Suppress CD8+ T Cells In Situ during Mucocutaneous Acute Graft-Versus-Host Disease ［J］. J Invest Dermatol， 2021， 141（5）：1177-1187.e3. doi:10.1016/j.jid.2020.09.018 |
| 32 | POBER J S， MEROLA J， LIU R， et al. Antigen Presentation by Vascular Cells ［J］. Front Immunol， 2017， 8： 1907. doi:10.3389/fimmu.2017.01907 |
| 33 | WHEWAY J， OBEID S， COURAUD P O， et al. The brain microvascular endothelium supports T cell proliferation and has potential for alloantigen presentation ［J］. PloS One， 2013， 8（1）： e52586. doi:10.1371/journal.pone.0052586 |
| 34 | WANG W， YE Y， DU Y， et al. EPC infusion ameliorates acute graft-versus-host disease-related endothelial injury after allogeneic bone marrow transplantation ［J］. Front Immunol， 2022， 13： 1019657. doi:10.3389/fimmu.2022.1019657 |
| 35 | NAJI A， SUGANUMA N， ESPAGNOLLE N， et al. Rationale for Determining the Functional Potency of Mesenchymal Stem Cells in Preventing Regulated Cell Death for Therapeutic Use ［J］. Stem Cells Transl Med， 2017， 6（3）： 713-719. doi:10.5966/sctm.2016-0289 |
| 36 | TI D， HAO H， TONG C， et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b ［J］. J Transl Med， 2015， 13： 308. doi:10.1186/s12967-015-0642-6 |
| 37 | LEE J W， FANG X， KRASNODEMBSKAYA A， et al. Concise review： Mesenchymal stem cells for acute lung injury： role of paracrine soluble factors ［J］. Stem Cells， 2011， 29（6）： 913-919. doi:10.1002/stem.643 |
| 38 | LI X， LIU L， YANG J， et al. Exosome Derived From Human Umbilical Cord Mesenchymal Stem Cell Mediates MiR-181c Attenuating Burn-induced Excessive Inflammation ［J］. EBioMedicine， 2016， 8： 72-82. doi:10.1016/j.ebiom.2016.04.030 |
| 39 | LIU W， ZHOU N， LIU Y， et al. Mesenchymal stem cell exosome-derived miR-223 alleviates acute graft-versus-host disease via reducing the migration of donor T cells ［J］. Stem Cell Res Ther， 2021， 12（1）： 153. doi:10.1186/s13287-021-02159-2 |
| 40 | ZHOU L， LIU S， WANG Z， et al. Bone Marrow-Derived Mesenchymal Stem Cells Modified with Akt1 Ameliorates Acute Liver GVHD ［J］. Biol Proced Online， 2019， 21： 24. doi:10.1186/s12575-019-0112-2 |
| 41 | HEGDE S， LEADER A M， MERAD M. MDSC： Markers， development， states， and unaddressed complexity ［J］. Immunity， 2021， 54（5）： 875-884. doi:10.1016/j.immuni.2021.04.004 |
| 42 | TIAN X， WANG T， SHEN H， et al. Tumor microenvironment， histone modifications， and myeloid-derived suppressor cells ［J］. Cytokine Growth Factor Rev， 2023，74：108-121. doi:10.1016/j.cytogfr.2023.08.002 |
| 43 | SPILLEBOUDT C， DE WILDE V， LEWALLE P， et al. Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease ［J］. Front Immunol， 2020， 11： 579151. doi:10.3389/fimmu.2020.579151 |
| 44 | DE WILDE V， VAN ROMPAEY N， HILL M， et al. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1 ［J］. Am J Transplant， 2009， 9（9）： 2034-2047. doi:10.1111/j.1600-6143.2009.02757.x |
| 45 | WANG K， LV M， CHANG Y J， et al. Early myeloid-derived suppressor cells （HLA-DR-/lowCD33+CD16-） expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease （GVHD） in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT ［J］. J Hematol Oncol， 2019， 12（1）： 31. doi:10.1186/s13045-019-0710-0 |
| 46 | VILLARINO A V， KANNO Y， O'SHEA J J. Mechanisms and consequences of Jak-STAT signaling in the immune system ［J］.Nat Immunol， 2017， 18（4）： 374-384. doi:10.1038/ni.3691 |
| 47 | LIU Y， LIAO S， BENNETT S， et al. STAT3 and its targeting inhibitors in osteosarcoma ［J］. Cell Prolif， 2021， 54（2）： e12974. doi:10.1111/cpr.12974 |
| 48 | KIM S Y， PARK M J， KWON J E， et al. Cucurbitacin E ameliorates acute graft-versus-host disease by modulating Th17 cell subsets and inhibiting STAT3 activation ［J］. Immunol Lett， 2018， 203： 62-69. doi:10.1016/j.imlet.2018.09.012 |
| 49 | PERSAUD S P， RITCHEY J K， KIM S， et al. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation ［J］. J Clin Invest， 2021，131（24）：e145501. doi:10.1172/jci145501 |
| 50 | 张雨峤， 梅伟健. 免疫检查点抑制剂治疗实体瘤的标志性成果 ［J］. 实用医学杂志， 2024， 40（2）： 272-277. |
| 51 | O'DONNELL J S， LONG G V， SCOLYER R A， et al. Resistance to PD1/PDL1 checkpoint inhibition ［J］. Cancer Treat Rev， 2017， 52： 71-81. doi:10.1016/j.ctrv.2016.11.007 |
| 52 | GENOVA C， DELLEPIANE C， CARREGA P， et al. Therapeutic Implications of Tumor Microenvironment in Lung Cancer： Focus on Immune Checkpoint Blockade ［J］. Front Immunol， 2021， 12： 799455. doi:10.3389/fimmu.2021.799455 |
| 53 | ASAKURA S， HASHIMOTO D， TAKASHIMA S， et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice ［J］. J Clin Invest， 2010， 120（7）： 2370-2378. doi:10.1172/jci39165 |
| 54 | NI X， SONG Q， CASSADY K， et al. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells ［J］. J Clin Invest， 2017， 127（5）： 1960-1977. doi:10.1172/jci91138 |
| 55 | PAN B， SHANG L， LIU C， et al. PD-1 antibody and ruxolitinib enhances graft-versus-lymphoma effect without increasing acute graft-versus-host disease in mice ［J］. Am J Transplant， 2021， 21（2）： 503-514. doi:10.1111/ajt.16275 |
| 56 | TSAI J J， VELARDI E， SHONO Y， et al. Nrf2 regulates CD4+ T cell-induced acute graft-versus-host disease in mice ［J］. Blood， 2018， 132（26）： 2763-2774. doi:10.1182/blood-2017-10-812941 |
| 57 | YI T， LI X， WANG E， et al. Activation of the Nuclear Erythroid 2-Related Factor 2 Antioxidant Responsive Element （Nrf2-ARE） Signaling Pathway Alleviates Acute Graft-Versus-Host Disease by Reducing Oxidative Stress and Inhibiting Infiltration of Inflammatory Cells in an Allogeneic Stem Cell Transplantation Mouse Model ［J］. Med Sci Monit， 2018， 24： 5973-5979. doi:10.12659/msm.908130 |
| 58 | YANG Y， LI J， LEI W， et al. CXCL12-CXCR4/CXCR7 Axis in Cancer： from Mechanisms to Clinical Applications ［J］. Int J Biol Sci， 2023， 19（11）： 3341-3359. doi:10.7150/ijbs.82317 |
| 59 | WU N， LIU R， LIANG S， et al. γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation ［J］. Front Immunol， 2021， 12： 687961. doi:10.3389/fimmu.2021.687961 |
| 60 | 王瑞娟， 李超， 段丽娟， 等. 氯普噻吨调节Akt/mTOR通路对人急性髓系白血病细胞自噬和凋亡的影响 ［J］. 实用医学杂志， 2023， 39（20）： 2584-2590. |
| 61 | MEHTA M， GOHIL D， KHATTRY N， et al. Prevention of acute graft-versus-host-disease by Withaferin a via suppression of AKT/mTOR pathway ［J］. Int Immunopharmacol， 2020， 84： 106575. doi:10.1016/j.intimp.2020.106575 |
| 62 | XIANG H， ZHU F， XU Z， et al. Role of Inflammasomes in Kidney Diseases via Both Canonical and Non-canonical Pathways ［J］. Front Cell Dev Biol， 2020， 8： 106. doi:10.3389/fcell.2020.00106 |
| 63 | ZHAO Y， HUANG J， LI T， et al. Berberine ameliorates aGVHD by gut microbiota remodelling， TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition ［J］. J Cell Mol Med， 2022， 26（4）： 1060-1070. doi:10.1111/jcmm.17158 |
| 64 | KUMAR GUPTA S， GOHIL D， DUTTA D， et al. Withaferin-A alleviates acute graft versus host disease without compromising graft versus leukemia effect ［J］. Int Immunopharmacol， 2023， 121： 110437. doi:10.1016/j.intimp.2023.110437 |
| 65 | CHEN W， SU G， XU Y， et al. Caspase-1 inhibition ameliorates murine acute graft versus host disease by modulating the Th1/Th17/Treg balance ［J］. Int Immunopharmacol， 2021， 94： 107503. doi:10.1016/j.intimp.2021.107503 |
| 66 | BASTIAN D， WU Y， BETTS B C， et al. The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease ［J］. Front Immunol， 2019， 10： 988. doi:10.3389/fimmu.2019.00988 |
| 67 | SONG Q， WANG X， WU X， et al. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity ［J］. Blood， 2021， 137（16）： 2243-2255. doi:10.1182/blood.2020006345 |
| 68 | GONG H， MA S， LIU S， et al. IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation ［J］. Front Immunol， 2018， 9： 2724. doi:10.3389/fimmu.2018.02724 |
| 69 | LI X， ZHANG C， CHEN W， et al. Protective effect of neutralizing anti-IL-18α monoclonal antibody on a mouse model of acute graft-versus-host disease ［J］. Oncol Rep， 2015， 34（4）： 2031-2039. doi:10.3892/or.2015.4176 |
| 70 | XING S， ZHANG X， LIU J H， et al. Host MyD88 signaling protects against acute graft-versus-host disease after allogeneic bone marrow transplantation ［J］. Clin Exp Immunol， 2019， 195（1）： 121-131. doi:10.1111/cei.13215 |
/
| 〈 |
|
〉 |